TNXP4:30 PMTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meetingtonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunologytonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meetingtonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026tonixpharma.com
TNXP4:30 PMTonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlightstonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patientstonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins UniversityPresentation / Abstract • Phase 1tonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026tonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Developmenttonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026Presentation / Abstract • Phase 1tonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial PainTrial Start • Phase 1tonixpharma.com
TNXP4:32 PMTonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026tonixpharma.com
TNXP4:35 PMTonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026tonixpharma.com
TNXP5:30 PMTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlightstonixpharma.com
TNXP8:00 AMTonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYA™ at the 8th International Congress on Controversies in FibromyalgiaPresentation / Abstract • Phase 3tonixpharma.com
TNXP4:30 PMTonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual MeetingPresentation / Abstracttonixpharma.com